India, Aug. 7 -- While reporting financial results for the second quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2025, primarily driven by strong underlying business performance across the portfolio and foreign exchange rates.
For fiscal 2025, Eli Lilly now projects earnings in a range of $20.85 to $22.10 per share and adjusted earnings in a range of $21.75 to $23.00 per share on revenues between $60.0 billion and $62.0 billion.
Previously, the company expected earnings in a range of $20.17 to $21.67 per share and adjusted earnings in a range of $20.78 to $22.28 per share on revenues between $58.0 billion and $61.0 billion.
googletag.cmd.push(function()...